Lonza announces successful completion of new GMP suite for growing viral vaccine and gene therapy business
Lonza, a global leader in the field of biologics manufacturing, today announced the successful completion of its new GMP clean room within its Houston, Texas operations. The clean room supports multiple types of viral vector and viral vaccine projects, with working volumes up to 2,000 liters.
“Since Lonza made the strategic decision to enter the viral manufacturing space less than two years ago, we have seen tremendous business growth,” said David Enloe, Lonza’s Head of Viral-based Therapeutics. “Many of our clients’ projects require higher working volumes than the gene therapy space has historically seen. This facility, along with the additions we’ve made to our process development and GMP manufacturing teams and the numerous other improvements made to our infrastructure and capabilities, will allow our clients to entrust their therapeutic and viral vaccine projects to Lonza from the early clinical phases up to commercial supply. We believe this represents a tremendous advantage for companies when they evaluate contract manufacturing alternatives.”
Lonza announced the launch of this project in May 2011.